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Abstract
Purpose: To discuss a case of ovarian fibromatosis/massive ovarian oedema, intra-abdominal fibromatosis, sclerosing
peritonitis and Meig’s syndrome. To review the reported therapeutic options.
Patients: Case report of a 27-year-old female with the combined pathology of ovarian fibromatosis/massive ovarian oedema,
intra-abdominal fibromatosis, sclerosing peritonitis and Meig’s syndrome.
Methods: This patient was treated with supportive care and cytotoxic chemotherapy.
Results: Despite the benign nature of the ovarian pathology, this patient presented with life-threatening complications.
Response to treatment was probably multi-factorial combining the effects of cytotoxics, use of steroids and good supportive
care. She remains in complete remission 4 years post completion of chemotherapy.
Conclusion: There are reports in the literature of ovarian fibromatosis/massive ovarian oedema, luteinised thecomas, intra-
abdominal fibromatosis and Meig’s syndrome occurring together in a variety of combinations. Treatment has been described
with radiotherapy, cytotoxic and non-cytotoxic chemotherapy regimens. This case provides a link between ovarian
fibromatosis/massive ovarian oedema, intra-abdominal fibromatosis, sclerosing peritonitis and Meig’s syndrome not
previously described.
Presentation of case
AP is a 27-year-old female who presented to her local
accident and emergency department in July 1999
with a history of bloating, abdominal pain and
altered bowel habit. On examination she was found
to have an abdominal mass and clinical ascites. An
ultra-sound scan confirmed bilateral ovarian enlarge-
ment with significant ascites. Beta-HCG, CA-125
and alpha-fetoprotein were within normal range. Past
medical history was significant for a termination of
pregnancy 2 years previously and a renal calculus.
There was no history of colonic polyps and no
significant family history. The patient was taking
the combined oral contraceptive at the time of
presentation.
A laparotomy with bilateral ovarian biopsies was
undertaken. At laparotomy, 4.5l of ascites were dra-
ined and the abdominal structures appeared normal.
The histology from the ovarian biopsies was
thought to be consistent with a sclerosing stromal
tumouroftheovary.Bilateralsalpingo-oophorectomy
and infra-colic omentectomy was then undertaken.
Following the second laparotomy the patient
became increasingly symptomatic with worsening
ascites and vomiting. A barium follow-through
revealed incomplete small bowel obstruction in the
pelvis as well as a 15cm stricture in the sigmoid
colon thought to be due to extrinsic compression.
A flexible sigmoidoscopy was performed and
biopsies taken which revealed inflammation only.
The subacute bowel obstruction was initially mana-
ged conservatively and the patient commenced total
parenteral nutrition (TPN).
At the end of July 1999 a third laparotomy was
undertaken for persistent small bowel obstruction
and clinical evidence of recurring mass in the
abdomen. At laparotomy the entire pelvis and
lower abdomen were involved in a retroperitoneal
mass matting the bowel together. Biopsies were
taken from the retroperitoneal mass, the omentum
and the sigmoid colon.
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with the new biopsies. Both ovaries were reported as
showing central stromal oedema with a zone of
increased cortical cellularity but sparing of the native
structures, there were few mitoses and both ovaries
showed evidence of torsion. An incidental cystade-
noma was noted in the right ovary. The overall
appearance was considered consistent with ‘imma-
ture fibromatosis’ and massive ovarian oedema.
The retroperitoneal histology showed fibroblastic
proliferations composed of long fascicles of spindle
cells invading the adipose tissue. Reactive mesothe-
lial cells and fibrinous exudates were seen on the
surface. The appearance was predominantly that
of intra-abdominal fibromatosis for which the
superficial areas showed indistinguishable sclerosing
peritonitis. The omental and sigmoid biopsies were
consistent with non-specific inflammation.
The patient was then transferred to the Royal
Marsden Hospital (RMH) for consideration of
chemotherapy for inoperable disease. On admission
to RMH the patient was clinically stable but
requiring on-going TPN for persistent small
bowel obstruction. Baseline CT scan showed an
extensive plaque of peritoneal tumour, loculated
ascites and gross compression of the stomach, small
and large bowel. There were large bilateral pleural
effusions.
In August 1999 she received a first cycle of
chemotherapy with doxorubicin and ifosfamide.
Four days following treatment she became acutely
hypoxic, tachycardic and oliguric. On transfer to
the High Dependency Unit (HDU) she was febrile,
pulse 140bpm, BP 130/80, O2 saturation 78% on
room air. She was treated for aspiration pneu-
monia and anti-coagulated for possible pulmonary
embolus. A large left pleural effusion was drained.
She responded well to antibiotics and fluid resuscita-
tion and was returned to the ward 3 days later.
An episode of neutropenic sepsis occurred during
the following 2 days but was managed without
complication.
A second cycle of chemotherapy was given on
schedule. Ifosfamide was replaced by DTIC due
to ifosfamide encephalopathy with the first cycle.
Two cycles of doxorubicin/DTIC were given
and re-imaging showed a partial remission of the
peritoneal disease. However, contrast imaging of the
GI tract revealed persistent high small bowel
obstruction. TPN was continued. An attempted
small bowel stent procedure failed.
Liver function became increasingly deranged.
Doxorubicin/DTIC were, therefore, replaced by
vinblastine and methotrexate for cycle 4. Cycles 5
and 6 comprised vinblastine with cyclophosphamide,
treatment being completed in November 1999. Post
treatment re-staging revealed a significant reduction
in both the peritoneal disease and the pleural
effusions. Unfortunately the patient was re-admitted
to HDU for an episode of sepsis requiring inotropic
support but recovered well.
Following completion of chemotherapy, the
obstructive GI symptoms persisted and the patient
remained dependent upon TPN. By March 2000
this appeared to be resolving slowly and NG feeding
was instituted. Her bowels started opening and TPN
was eventually stopped. Liver function remained
persistently deranged. Hepatitis screen was negative.
A liver biopsy was eventually undertaken which
showed exogenous iron overload and cholestasis
consistent with TPN. HFE genotyping was not
consistent with haemochromatosis.
In May 2000, 11 months following admission to
the referring hospital, the patient was discharged
home. Imaging at this time showed virtual complete
resolution of effusions, small volume ascites, sig-
nificant reduction in peritoneal disease, hepatosple-
nomegaly and no evidence of GI obstruction.
Following discharge a large pericardial effusion
required drainage and a window procedure in
August 2000. A rectovaginal fistula has been
noted which is relatively asymptomatic and under
surveillance only. An abdominal scar revision was
successfully undertaken by the plastic surgeons in
June 2001 for cosmetic reasons. Otherwise, liver
function has normalised, the patient has gained
weight (though remains below ideal body weight)
and has returned to normal active life. The most
recent CT scan in February 2003 showed continued
complete remission 4 years following completion
of chemotherapy.
Figures 1–4 show the biopsy specimens taken
from the case presented. They demonstrate the
histopathological changes seen in massive ovarian
oedema, ovarian fibromatosis, sclerosing peritonitis
and intra-abdominal fibromatosis. Figure 5 is taken
from pre-chemotherapy CT images which show the
dense mass of solid intra-abdominal fibromatosis.
Figure 6 is the most recent CT image showing
complete resolution of the intra-abdominal
fibromatosis and normal intra-abdominal structures.
Introduction
Fibromatosis describes a group of fibrous tissue
proliferations that, although benign, can be locally
invasive but do not metastasise.
1 X-chromosome
inactivation molecular analyses have confirmed
these tumours to be clonal, thus identifying them
as neoplasms and not products of an inflammatory
response.
2 Similarly, molecular analysis has shown
recurrent fibromatosis within an individual to be
derived from the same cell clone as the primary
lesion.
2 The fibromatoses have a predilection
for certain anatomic sites and are divided into two
types – superficial and deep.
1 Superficial fibroma-
toses arise from fascia or aponeuroses, rarely involve
deep structures and are small and slow growing.
1
114 E. L. SpurrellDeep fibromatoses principally involve the deep
muscles of the trunk and extremities (including the
abdomen and pelvis) and tend to be more aggres-
sive with a high recurrence rate.
1 Deep fibromatoses
are also referred to as desmoid tumours. Intra-
abdominal fibromatosis is divided into pelvic,
mesenteric, retroperitoneal and intra-abdominal
desmoid tumours associated with Gardner’s
Syndrome.
1 Gardner described the association of
familial intestinal polyposis, osteomas, fibromas and
epidermal or sebaceous cysts in 1951.
1 This is an
autosomal dominant condition not associated with
the case under discussion.
This is a case of immature ovarian fibromatosis
associated with massive ovarian oedema, intra-
abdominal involvement, sclerosing peritonitis
Fig. 2. The ovarian cellular cortex is composed of a spindle cell proliferation with entrapment of numerous ovarian structures consistent
with ovarian fibromatosis.
Fig. 1. Ovary showing a zone of increased cortical cellularity with central stromal oedema, typical of massive ovarian oedema.
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cellular fibroblastic tumour-like lesions of the ovary
have been described in the literature as ‘thecomas’,
‘fibromatosis’, ‘fibrothecomas’ and ‘luteinised the-
comas’.
3 Thecomas and fibromas represent tumours
of the ovarian stroma. Thecomas are histologically
composed of lipid-containing cells and fibromas
almost entirely of spindle cells. There is, however,
considerable histological overlap between the two,
such that intermediate tumours are often termed
fibrothecomas.
4 Luteinised thecomas are composed
of nests of pale luteinised cells within a background
population of spindle cells and are known to be
associated with reactive peritoneal proliferations
showing fibrosis, surface fibrin, chronic inflamma-
tion and focal mesothelial hyperplasia known
Fig. 4. Long fascicles of spindle cells infiltrating underlying adipose tissue from the retroperitoneal biopsy consistent with
intra-abdominal fibromatosis.
Fig. 3. Proliferation of mesothelial cells associated with fibrinous exudates and fibrosis are seen on the surface of the retroperitoneal
biopsy, features of sclerosing peritonitis.
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resemble immature fibromatosis but are usually
unilateral and oestrogenic, unlike fibromatosis
that is endocrinologically inactive and often bilat-
eral.
3 Common to all these conditions is their
young age at onset, presentation with abdominal/
pelvic pain, pelvic swelling, occasional associa-
tion with ascites and pleural effusions and with
massive ovarian oedema.
3 There are also reported
associations with exposure to antiepileptic drugs
3,5
and beta-blockers.
3,6
Massive ovarian oedema describes the accumula-
tion of fluid within the ovarian stroma.
7 It is said to
occur in younger females (average age 19–22 years),
causes abdominal/pelvic pain and may be associated
with hormonal irregularities causing menstrual
disturbance, virilisation and occasionally precocious
puberty.
7,8 It is usually a unilateral phenomenon, the
Fig. 5. Baseline CT taken in August 1999 showing dense fibrosis within the abdomen. The main tumour plaque has been
outlined by arrowheads. There are no visible gas-filled bowel loops due to persistent small bowel obstruction and physical compression
of the bowel by tumour.
Fig. 6. CT taken in February 2003 showing resolution of the dense abdominal fibromatosis. There are visible normal gas-filled loops of
bowel as the GI tract is no longer obstructed.
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left.
8 One theory pertaining to the pathogenesis
of massive ovarian oedema suggests that there is
disruption of ovarian lymphatic and venous drainage
due to intermittent partial torsion.
7,8 An analysis of
18 cases of massive ovarian oedema showed that in
14 there was torsion of the ovaries.
8 In favour of this
theory is the observation that the ovaries revert to
normal size once the torsion has been corrected
by ovarian suspension.
8 The relationship between
ovarian fibromatosis and massive ovarian oedema is
not clear. A study of 25 patients with ovarian
enlargement in 1984 showed that 14 cases had
fibromatosis as the predominant pathology, six of
which also had massive ovarian oedema; 11 cases
showed massive ovarian oedema as the predominant
pathology, eight of which contained foci of fibroma-
tosis; seven of the 25 cases showed evidence
of ovarian torsion.
9 It would appear that massive
ovarian oedema is associated with both fibromatosis
and ovarian torsion, but which comes first the torsion
or the fibromatosis?
There are two theories to explain the relationship
between ovarian fibromatosis and torsion. The first
states that the primary pathology is fibromatosis that
causes ovarian torsion and then massive ovarian
oedema.
3 The second theory states that torsion itself
causes fibromatosis by stimulating local platelets and
macrophages to secrete growth factors that induce
massive fibroblastic proliferation and oedema.
3 It is
thought that patients presenting in the acute phase of
this process exhibit a mitotically active ‘immature’
fibromatosis (as in the case discussed here) and those
presenting in the resolving phase exhibit a ‘mature’
sclerotic fibromatosis.
3
Meig’s Syndrome describes the combination of
ovarian fibroma associated with ascites and hydro-
thorax.
10 Meig’s syndrome is mentioned due to the
otherwise unexplained massive pleural effusions seen
in our patient and other similar cases in the
literature. It is thought that the ovarian tumour
produces ascitic fluid that migrates to the pleural
cavity via diaphragmatic lymphatics. The effusions
and ascites are usually transudative but blood
stained ascites is seen in cases associated with
ovarian torsion. Characteristic of the syndrome is
the disappearance of the ascites and hydrothorax
following resection of the ovarian tumour.
The case presented represents the previously
undescribed occurrence of sclerosing peritonitis in
association with ovarian fibromatosis/massive ovarian
oedema (previously, sclerosing peritonitis has only
been reported in association with luteinised the-
comas). The pleural and pericardial effusions in
association with ascites suggests associated Meig’s
syndrome. Our patient also showed radiological and
biopsy proven evidence of intra-abdominal fibroma-
tosis, or desmoid, a poorly understood phenomenon
very rarely reported to occur in association with
ovarian fibromatosis. The management of the
fibromatoses is dependent upon the site of disease
and its associated morbidity, but data are scanty and
varied, as discussed below.
Management
Discussed below is a review of the literature
concerning the management of fibromatosis.
Information relating specifically to the above case is
anecdotal, therefore, included is discussion regard-
ing management of fibromatosis in general. When
referring to intra-abdominal disease, this includes
pelvic disease. The literature discussed below is
limited, where possible, to articles concerned
mainly with intra-abdominal disease (as opposed to
trunk and extremity) and not related to Gardner’s
syndrome.
Surgery
In the first instance, surgical resection of abdominal
desmoid tumours is the treatment of choice where
possible. Complete excision of abdominal desmoid
tumours is often difficult due to their close proximity
to vital structures. There is debate in the literature
as to whether positive or negative surgical margins
influence local recurrence rates. A review of 130
patients with retroperitoneal soft tissue sarcomas
showed a local recurrence rate of 63% post local
excision versus 39% following a wide resection.
11
Similarly, a retrospective review of 189 patients with
desmoid tumours, seven of which were intra-
abdominal, showed a 10 year post-operative relapse
rate of 27% in patients with negative surgical margins
and 54% in those with positive margins.
12 A meta-
analysis of 22 published analyses included 845
patients with desmoid tumours, 60 of which were
intra-abdominal, and showed a local control rate of
72% with negative surgical margins versus 41% with
postive margins.
13 Alternatively, an analysis of 103
patients with trunk and extremity desmoid tumours,
none of which were intra-abdominal, showed a local
recurrence rate of 22% in those with positive
resection margins and 24% in those with negative
margins.
14 They suggest that surgery that preserves
structure and function should be the goal, not
negative resection margins.
14
Radiotherapy
The literature pertaining to radiotherapy for desmoid
tumours mainly involves extremity or abdominal wall
tumours. Information regarding radiotherapy to
intra-abdominal tumours is minimal. The meta-
analysis of 22 articles mentioned above compared
surgery versus radiotherapy for patients with
desmoid tumours (excluded in this analysis were
patients with Gardner’s).
13 Cases of intra-abdominal
118 E. L. Spurrellfibromatosis represented 7% of the total number of
patients analysed in this publication. This paper
suggested that the addition of radiotherapy to surgery
improved local control rates for post-operative
negative surgical margins (72 vs. 94% with addition
of radiotherapy) and positive surgical margins (41 vs.
75% with addition of radiotherapy).
13 Similar find-
ings were published in the retrospective review
of 189 cases of desmoid tumours also mentioned
above, whereby optimum management was consid-
ered to be surgery with negative margins but
adjuvant radiotherapy considerably offset the effect
of positive surgical margins (10-year relapse rate
with positive margins, 54 vs. 25% with addition of
radiotherapy).
12
In these large analyses, intra-abdominal desmoid
tumours are significantly under-represented making
it difficult accurately to extrapolate the results to
these tumours. Intra-abdominal disease is often
difficult to irradiate due to the large field required,
and radiotherapy carries the potential for gastro-
intestinal side effects in patients potentially already
experiencing GI morbidity. A published analysis of
54 desmoid tumours treated with surgery and
radiotherapy reported a sub-analysis of the six
abdominal tumours within the cohort, and found
that there was an increased frequency of treatment
failure in the abdominal tumours.
15 Their explana-
tion for this was that the abdominal tumours
were more likely to have spread further making it
difficult to encompass all of the disease within the
radiotherapy field.
15
Non-cytotoxic chemotherapy
Hormonal treatment for desmoid tumours is
the major non-cytotoxic chemotherapy reported in
the literature. Abdominal wall desmoid tumours
have been noted to occur more commonly in young
women, pregnant women or in the first year
following gestation.
1 For this reason, it is believed
possible that tumour growth is under the influence of
oestrogen and progesterone. Oestrogen receptors
and anti-oestrogen binding sites have been demon-
strated in desmoid tumours.
16 A study of 15 desmoid
tumours found oestrogen receptors to be present in
33%, with equal incidence in males and females but
higher receptor content in females.
16 Anti-oestrogen
binding sites were found in 79%.
16
Other non-cytotoxic agents include non-steroidal
anti-inflammatory drugs (NSAIDs) and glucocorti-
coids. Use of these agents originated from mouse
tumour models, showing inhibition of tumour
growth in the absence of products of arachidonic
acid metabolism as a result of phospholipase A2
inhibition.
17 Glucocorticoids are known to inhibit
phospholipase A2. NSAIDs reduce arachidonic acid
metabolism via inhibition of cyclo-oxygenase.
Table 1 is a summary of the literature pertaining to
intra-abdominal desmoid in the absence of
Gardner’s syndrome. Much of the data are anecdotal
and many of the agents have been given in
combination, making it difficult to isolate efficacy.
The main hormonal agents used with some success
are tamoxifen and progesterone.
18–22 Others include
LHRH analogues, medroxyprogesterone acetate and
toremifene (a tamoxifen derivative).
23,24 There are
anecdotal reports of use of glucocorticoids and
NSAIDs in combination with tamoxifen.
19–21
There are two identifiable reports of non-cytotoxic
agents used in cases very similar to the one presented
in this report. The first involves a case of ovarian
fibromatosis associated with diffuse intra-abdominal
fibromatosis treated with tamoxifen and iv steroid
resulting in complete resolution of bowel obstruc-
tion.
20 The second report includes a case of
luteinised thecoma of the ovary with associated
scerosing peritonitis.
25 The sclerosing peritonitis,
which persisted following resection of the ovaries,
was treated with i.v. hydrocortisone resulting in
resolution of ascites and symptoms.
25 This patient
was successfully re-challenged with hydrocortisone 2
months later when the disease flared.
25
Cytotoxic chemotherapy
Despite the benign classification of fibromatosis,
there has been success in treating unresectable
tumours with chemotherapy. Table 2 is a summary
of the different regimens that have been employed
Table 1. Non-cytotoxic chemotherapy use in desmoid tumours (RR, response rate; CR, complete response; PR, partial response; SD,
stable disease)
Year of
publication
Number of
patients
Gardner’s
syndrome
Number of
abdominal
tumours
Agent Response
1990
23 1 No 1 LHRH (Zoladex)þ
medroxyprogesterone acetate
PR
1991
18 1 No 1 Tamoxifen CR
1996
19 1 No 1 Tamoxifenþsulindac PR
1993
20 1 No 1 TamoxifenþIV steroid PR
1995
21 1 No 1 Tamoxifenþprednisolone PR
1994
24 1 No Retroperitoneal Toremifene PR
1983
22 11 No Unstated Progesterone RR 54.5%, SD 18%
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cin-based with good results, but are limited
by toxicity following cumulative dosing. Weekly
methotrexate and vinblastine is an effective regimen
with minimal toxicity, enabling patients to remain on
treatment for prolonged periods of time (longest 12
months).
26,27 Peripheral neuropathy can be a treat-
ment-limiting toxicity with this regimen that has
been successfully overcome by substituting vinblas-
tine for vinorelbine with similar good results.
28
Limiting all of the studies are the small patient
numbers and variation in regimens between studies
and occasionally within studies. Importantly, as well
as objective responses being reported, many articles
have also mentioned the significant palliation of
symptoms achieved with cytotoxic chemotherapy.
Conclusion
The case presented here represents the rare com-
bined occurrence of ovarian fibromatosis and mas-
sive ovarian oedema together with sclerosing
peritonitis, intra-abdominal fibromatosis and
Meig’s syndrome. The origin of the extra-ovarian
intra-abdominal pathology reported in this case, and
other similar cases, is debated. In some reports,
biopsies of extra-ovarian sites have revealed nodules
of tumour similar to that seen in the resected ovaries
postulating that cells may have become detached
from the ovarian tumour and migrate into the
peritoneal cavity by way of the ascites to implant
elsewhere.
5,6,20,29 Other reports have described a
generalised sclerosing peritonitis associated with
ovarian luteinised thecomas and it is suggested that
the ovarian tumour may be producing a fibrosis-
inducing substance.
6,30–33 Against the latter argu-
ment is the observation that in many cases the
peritoneal pathology progresses despite resection
of the ovarian tumours, some patients requiring
multiple laparotomies for recurrent small bowel
obstruction.
6,25,30,34
Despite the benign nature of the ovarian
tumours, there is significant associated morbidity.
The intra-abdominal disease frequently causes
recurrent problems with small bowel obstruction
sometimes requiring multiple resections. Fatal
pulmonary emboli have been reported twice in the
literature.
29,30 Both occurred post laparotomy for
small bowel obstruction and may represent the
increased thrombotic risk associated with the post-
operative state or possibly a hypercoagulable state
associated with the intra-abdominal pathology.
In conclusion, there are anecdotal reports in the
literature of ovarian fibromatosis/massive ovarian
oedema, intra-abdominal fibromatosis, luteinised
thecomas, sclerosing peritonitis and Meig’s
syndrome occurring together in a variety of combi-
nations.
4–6,9,20,25,29–34 Previously in the literature,
sclerosing peritonitis has only been reported to occur
in the presence of ovarian luteinised thecomas. Our
case is unique being the first to describe the
occurrence of sclerosing peritonitis in association
with ovarian fibromatosis. The case is also unique
being the first to describe management of these
combined pathologies with cytotoxic chemotherapy.
These conditions remain rare, poorly understood
and potentially life threatening. Therapeutic options
are unclear and there are anecdotal reports of
spontaneous regressions.
35 Although without
chemotherapy it is unlikely that complete disease
resolution would have occurred, response to treat-
ment was almost certainly multi-factorial, combining
the effects of cytotoxic drugs, use of steroids and
good supportive care. Use of cytotoxic chemotherapy
in the face of life-threatening complications appears,
therefore, to offer some therapeutic benefit to these
conditions.
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